Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.




This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Oncologists who Treat RCC (US)(?)

Council Members in this Study Group: 41

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

What is a GLG Leader?
Donald Fleming, MD, Division Head of Hematology and Oncology, Davis Health System, Inc.Donald Fleming, MD
Division Head of Hematology and Oncology
Davis Health System, Inc.

Donald Fleming, MD, is the Head of Hematology-Oncology at the Medical Center of Vincennes. Previously, Dr. Fleming was a Tenured Professor in the Division of Hematology-Oncology at University of Louisville. He has published over 25 manuscripts in peer-reviewed journals and remains involved in clinical...


62 recent news post(s)
Taral Patel, MD, Oncologist, Mid Ohio Oncology Hematology Inc.Taral Patel, MD
Oncologist
Mid Ohio Oncology Hematology Inc.

Taral Patel, MD, is an Oncologist in private practice with Mid Ohio Oncology-Hematology, Inc. He treats patients with both cancer and blood disorders. Dr. Patel has been a principal investigator for multiple clinical trials in colon cancer, lung cancer, lymphoma, and growth factor. He has been on the...


8 recent news post(s)

Related Study Groups

GLG NewsSMAnalyses by this Study Group's Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
Erbitux and Lung cancer | 05-23-2008
Analysis of: Phase II trial of gemcitabine, docetaxel, and cetuximab in advanced non-small-cell lung cancer (NSCLC). | www.abstract.asco.org
Author: Donald Fleming, MD, Division Head of Hematology and Oncology, Davis Health System, Inc.

Erbitux has had a few high level trials in Non small lung cancer So far there does not appear to be a contributuion to chemotherapy Maybe we are going about it the wrong way

BRCA Mutations less risky than thought | 05-19-2008
Analysis of: Cancer-Gene Test Boosts Myriad's Sales | online.wsj.com
Author: Donald Fleming, MD, Division Head of Hematology and Oncology, Davis Health System, Inc.

New data indicates risk of invasive breast cancer in women with either BRCA mutation maybe less than previuosly thought This new information will adversely impact Myriad's business

ASA404 approach in treating lung cancer | 05-09-2008
Analysis of: ASA404 begins pivotal trial to explore new approach in treating lung cancer, the leading cause of cancer death | www.pipelinereview.com
Author: Donald Fleming, MD, Division Head of Hematology and Oncology, Davis Health System, Inc.

ASA404 begins pivotal trial to explore new approach in treating lung cancer ASA404 is a drug that helps chemo treat lung cancer yet eliminate exisiting blood vessels supplying the tumors

Hedgehog pathwa drugs and chemotherapy | 05-07-2008
Analysis of: Curis Announces Genentech's Initiation of Hedgehog Antagonist Phase II Clinical Trial In Metastatic Colorectal Cancer | www.pipelinereview.com
Author: Donald Fleming, MD, Division Head of Hematology and Oncology, Davis Health System, Inc.

Hedgehog path new and will improve on chemo/biologic therapy available for colorectal cance Past attempts at ading to regimens have not always been successful ie PACE

Why Xeloda can't eliminate 5FU | 04-21-2008
Analysis of: Randomized Phase III Study of Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid Plus Oxaliplatin As First-Line Therapy for Metastatic Colorectal Cancer | jco.ascopubs.org
Author: Donald Fleming, MD, Division Head of Hematology and Oncology, Davis Health System, Inc.

Xeloda has time after time demonstrated to be as good if not better than 5FU Xeloda continues to lag behind 5FU in the US Recent trial results are not likely to change things overnight

View All GLG News by members of this Study Group

Most Common Company Types:

  • Academic Medical Center/Hospital or Clinic
  • Office Based Private Practice or Clinic

Most Common Job Types:

  • Physician - Attending Physician
  • Physician - Director
  • Physician - Division Head
  • Partner

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics